Nusara Satproedprai

Nusara Satproedprai

Auto-generated profile, based on publicly available information

Nusara Satproedprai

Eastern Economic Corridor Office of Thailand (EECO), Bangkok 10500

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
Vorasuk ShotelersukVorasuk Shotelersuk
Vorasuk Shotelersuk
DWDuangdao Wichadakul
Duangdao Wichadakul
CNChumpol Ngamphiw
Chumpol Ngamphiw
CSChalurmpon Srichomthong
Chalurmpon Srichomthong
CPChureerat Phokaew
Chureerat Phokaew
STSissades Tongsima
Sissades Tongsima

20 April 2021 in Heliyon
Verified
Journal Article
Open access
PDF file
NCNoppadol Chanhom
Noppadol Chanhom
SWSukanya Wattanapokayakit
Sukanya Wattanapokayakit
NSNusara Satproedprai
Nusara Satproedprai
SSSupharat Suvichapanich
Supharat Suvichapanich
SMSurakameth Mahasirimongkol
Surakameth Mahasirimongkol
JJJiraphun Jittikoon
Jiraphun Jittikoon
Antituberculosis drug-induced liver injury (ATDILI) is the common adverse reaction of antituberculosis drugs. Glutathione S-transferases (GSTs), which are phase II metabolizing enzymes for detoxification, are recognized as potential mediators of hepatotoxicity. However, role of GSTs polymorphisms in ATDILI pathogenesis has never been observed in Thais. This study aimed to investigate associations between GSTs and ATDILI susceptibility. This retrospective case-control multicentered study was conducted by the collaboration from ten secondary and tertiary care hospitals across Thailand, including Northern, Central, and Southern parts of Thailand. We enrolled 80 tuberculosis (TB) patients with ATDILI and 174 those without ATDILI into the study. Polymerase chain reaction (PCR) was used to determine genetic polymorphisms of GSTM1 and GSTT1 genes. CYP2E1 genotyping data were derived from microarray data. We illustrated that GSTT1 null and GSTM1/GSTT1 dual null genotypes were correlated with an increased risk of ATDILI with odds ratio (OR) at 1.83 (95% confidence interval (CI), 1.00 to 3.35; P = 0.049) and 2.12 (95%CI, 1.02 to 4.38; P = 0.044), respectively. Interestingly, GSTT1 null and GSTM1/GSTT1 dual null genotypes were found to be correlated with an increased risk of ATDILI in Thai TB patients who carried CYP2E1 wild type phenotype with OR 2.99 (95%CI, 1.07 to 8.39; P = 0.037) and 3.44 (95%CI, 1.01 to 11.71; P = 0.048), respectively. Collectively, GSTT1 null and GSTM1/GSTT1 dual null genotypes were associated with a higher risk of ATDILI in Thai TB patients, which may serve as alternative genetic biomarkers for ATDILI.

20 October 2021 in Jornal de Pediatria
Verified
Journal Article
Open access
NNNarongsak Nakwan
Narongsak Nakwan
SMSurakameth Mahasirimongkol
Surakameth Mahasirimongkol
NSNusara Satproedprai
Nusara Satproedprai
TCTassamonwan Chaiyasung
Tassamonwan Chaiyasung
PKPunna Kunhapan
Punna Kunhapan
CCChariyawan Charalsawadi
Chariyawan Charalsawadi
To explore possible genes related to the development of persistent pulmonary hypertension of the newborn (PPHN). The authors identified 285 single nucleotide polymorphisms (SNPs) of 11 candidate genes (BMPR2, EPAS1, PDE3A, VEGFA, ENG, NOTCH3, SOD3, CPS1, ABCA3, ACVRL1, and SMAD9), using an Illumina Asian Screening Array-24 v1.0 BeadChip Array. The FastLmmC and R package was used for statistical analyses. The chi-square test and Cochrane-Armitage trend test were used to compare the allele and genotype frequencies between the groups and to test the genetic models, respectively. A total of 45 PPHN infants and 294 control subjects were analyzed. The most common cause of PPHN was meconium aspiration syndrome. Among the 285 SNPs, 17 SNPs from 6 candidate genes (BMPR2, EPAS1, PDE3A, VEGFA, ENG, and NOTCH3) were significantly associated with PPHN (P < 0.05). After using the Bonferroni correction (P < 0.00018), only the rs17034984 SNP located in intron 1 of the EPAS1 gene remained significantly different between the PPHN and control subjects (P = 0.00014). The frequency of the TC/TT genotype of rs17034984 in the gene with the dominant model was significant in the patients with PPHN (OR = 5.38, 95% CI: 2.15–13.49). The T allele frequency of rs17034984 in the gene showed a significant difference compared with the control subjects (OR = 4.89, 95% CI: 2.03–11.82). The present study suggests that the rs17034984 variant of EPAS1 gene is associated with PPHN.

2 February 2026 in Nature Health
Verified
Journal Article
Closed access
PDF file
Vorasuk ShotelersukVorasuk Shotelersuk
Vorasuk Shotelersuk
STSissades Tongsima
Sissades Tongsima
MPManop Pithukpakorn
Manop Pithukpakorn
SMSurakameth Mahasirimongkol
Surakameth Mahasirimongkol
JEJakris Eu-Ahsunthornwattana
Jakris Eu-Ahsunthornwattana
SSSupakit Sirilak
Supakit Sirilak

1 September 2026 in Health Affairs Scholar
Verified
Journal Article
Open access
APAdena Li Tyin Peh
Adena Li Tyin Peh
Yot TeerawattananonYot Teerawattananon
Yot Teerawattananon
JYJeanette Xue Yan Yuen
Jeanette Xue Yan Yuen
NCNordin Charafi
Nordin Charafi
DTDicky Levenus Tahapary
Dicky Levenus Tahapary
Wenjia ChenWenjia Chen
Wenjia Chen
Background: Precision medicine (PM) adoption is accelerating across Asia, but implementation remains uneven due to differences in financing, infrastructure, governance, and health-system readiness. Objectives: To examine how six Asian countries (Singapore, South Korea, China, Malaysia, Thailand, and Indonesia) adopt, finance, and integrate PM technologies, and identify common implementation patterns and challenges. Methods: A landscape review of peer-reviewed literature, government publications, and HTA reports (2010-2026) was conducted, supplemented by stakeholder consultations. PM applications were grouped into public health screening (hereditary breast and ovarian cancer [HBOC] and familial hypercholesterolemia [FH] cascade testing), next-generation sequencing (NGS) applications (rare diseases, oncology, pharmacogenomics), and AI-enabled PM. Evidence was synthesized across access, awareness, reimbursement, and implementation. Results: Public health genomic screening demonstrated the highest implementation readiness, followed by precision oncology, while rare disease diagnostics remained infrastructure-dependent and pharmacogenomics and AI-enabled PM platforms were at earlier stages. Four readiness profiles emerged: highly aligned systems; reimbursement-constrained systems with strong governance and infrastructure; systems strengthening governance, public financing and infrastructure; and strategy-led systems expanding implementation through pilot programs and referral centers. Conclusions: PM implementation across Asia remains heterogeneous. The identified readiness profiles highlight governance, financing, and infrastructure priorities for sustainable and equitable PM diffusion.